Bio Pharma Dive
NOVEMBER 23, 2020
Data from two late-stage trials showed the shot to be, on average, 70% effective against COVID-19, an encouraging finding. The lower dose tested, however, outperformed a higher dose.
World of DTC Marketing
NOVEMBER 23, 2020
SUMMARY: Pfizer’s ad in newspapers around the U.S. shows that they are ready to lead the fight against COVID-19 and in the process establish that their vaccine is safe and has been well tested. Pfizer ran an ad today that is superb. The ad, for it’s COVID-19 vaccine, has a headline that says “courage” and details that 43,661 people tested their vaccine and ends with “science will win” This ad send out a reassurance to vaccine skeptics who have come to believe
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
NOVEMBER 23, 2020
The smaller biotech vowed to push forward, although the pill's inability to prevent heart failure death may complicate its plans to win approval.
BioSpace
NOVEMBER 23, 2020
As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. FDA and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bio Pharma Dive
NOVEMBER 23, 2020
The large drugmaker will pay $425 million to acquire OncoImmune, which is developing a treatment for severe coronavirus disease.
NY Times
NOVEMBER 23, 2020
The billionaire is working with the W.H.O., drugmakers and nonprofits to defeat the coronavirus everywhere, including in the world’s poorest nations. Can they do it?
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
NOVEMBER 23, 2020
Two months after he was stepped down from the role of chief executive officer of Legend Biotech, Fangliang “Frank” Zhang has been arrested for smuggling genetic resources from the People’s Republic of China.
BioPharma Reporter
NOVEMBER 23, 2020
Study data from leading COVID-19 vaccine candidates suggests they may be effective in older people.
BioSpace
NOVEMBER 23, 2020
Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals.
pharmaphorum
NOVEMBER 23, 2020
AstraZeneca is preparing to file its COVID-19 vaccine with regulators after phase 3 trial results showed it is up to 90% effective. AZ made the announcemen t as the UK regulator reportedly gears up to make a decision on the rival vaccine from Pfizer and BioNTech, ahead of counterparts in the US and Europe. Results from trials conducted in the UK and Brazil showed an efficacy of 90% in 2,741 patients receiving the vaccine as a half dose, followed by a full dose at least one month apart.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
NOVEMBER 23, 2020
Following a year-long probe into tech giants Amazon, Apple, Facebook, and Google, the House Judiciary antitrust subcommittee has its next target in its sights – big pharma.
NY Times
NOVEMBER 23, 2020
The drug maker said its vaccine candidate was 70 percent effective on average, and potentially up to 90 percent effective, at preventing Covid-19 in an early analysis.
BioSpace
NOVEMBER 23, 2020
To support its long-term goals, the Swiss pharma giant is initiating a share-buyback program of up to $2.5 billion that is expected to be carried out over the next few months.
BioPharma Reporter
NOVEMBER 23, 2020
Sanofiâs MenQuadfi becomes the first quadrivalent meningococcal conjugate vaccine available in Europe in a fully liquid presentation, avoiding the need for vaccine reconstitution.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
XTalks
NOVEMBER 23, 2020
With Thanksgiving just around the corner and COVID-19 cases continuing to rise, grocers and retailers are bracing once again for customer stockpiling. But this time around, some grocery chains are implementing previously used tactics to curb the inevitable shortages of Thanksgiving staples and other food items. While many national chains, including Kroger, Publix and H-E-B, have already limited purchasing quantities for some home essentials, they are looking ahead to see which food products migh
BioPharma Reporter
NOVEMBER 23, 2020
AstraZeneca says interim analysis of clinical trials in the UK and Brazil of its candidate COVID-19 vaccine being developed in partnership with the University of Oxford - AZD1222 - showed the vaccine was highly effective in preventing COVID-19, the primary endpoint.
Scienmag
NOVEMBER 23, 2020
Credit: The image was taken in the Laboratory of Micro and Nano Mechanics, CDMM at Skoltech. A research team from the Center for Design, Manufacturing and Materials at Skoltech has recently published a study focusing on multifunctional materials created through the addition of carbon nanoparticles to polymer matrices, designed to allow self-diagnostic monitoring through an […].
BioPharma Reporter
NOVEMBER 23, 2020
Regeneronâs casirivimab and imdevimab antibody cocktail (formerly known as REGN-COV2 or REGEN-COV2), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Scienmag
NOVEMBER 23, 2020
Credit: Maria Hällfors Siberian primrose, a species protected under the Habitats Directive of the European Union, spread northward from southern areas to the current Bothnian Bay as well as, through another route, to northern Norway with the gradually receding ice after the Ice Age. Compared to today, the warming of the climate was very slow […].
pharmaphorum
NOVEMBER 23, 2020
German digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet age-related macular degeneration (AMD), a leading cause of blindness. The Munich-based company is launching the educational See What’s Next app in collaboration with Novartis, which sells the wet AMD medicines Beovu (brolucizumab) and Lucentis (ranibizumab), and has also been a big proponent of digital health technologies.
Scienmag
NOVEMBER 23, 2020
Credit: (U.S. Navy photo by Corey Egler) ARLINGTON, Va.–The American Society of Naval Engineers (ASNE) has awarded its most prestigious accolade–the Harold E. Saunders Award for Lifetime Achievement–to E. Anne Sandel, the executive director of the Office of Naval Research (ONR), for outstanding contributions to the Navy and nation over her career.
XTalks
NOVEMBER 23, 2020
Adding to recent announcements from Pfizer and Moderna on the efficacy of their COVID-19 vaccine candidates, AstraZeneca and Oxford revealed today that their vaccine contender is 70 percent effective, and could be as high as 90 percent. In an interim, pooled analysis of Phase II/III clinical trials for the vaccine (AZD1222 or ChAdOx1 nCoV-2019) being conducted in the UK and Brazil (in the COV002 Phase II/III trial in the UK and the COV003 Phase III trial in Brazil, respectively), the vaccine was
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Scienmag
NOVEMBER 23, 2020
How ancient fish may have prepared for life on land Credit: Dr Alice Clement, Flinders University A new study adds another layer to the remarkable evolutionary transition of life from water to land on Earth. The international study of the prehistoric ‘relic’ tetrapods, including salamander and lobe-finned lungfish and coelacanths, adds another perspective to the […].
Outsourcing Pharma
NOVEMBER 23, 2020
The pharma giant and the clinical-stage drug developer will join on a pilot study investigating a candidateâs potential in overcoming resistance of a cancer drug.
Scienmag
NOVEMBER 23, 2020
UTD team will play key role in device test, study response to electrodes Credit: University of Texas at Dallas Implanting a device into the brain to generate a rough perception of sight for people with blindness may sound like the stuff of science fiction, but researchers from The University of Texas at Dallas and partner […].
BioSpace
NOVEMBER 23, 2020
Physicians are worried that a lack of transparency about side effects might prevent people from going back for a second dose, or even getting the first one.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Scienmag
NOVEMBER 23, 2020
Two-phase theory applies to diseases like Alzheimer’s, Parkinson’s, muscle atrophy Credit: Jeff Fitlow/Rice University HOUSTON – (Nov. 23, 2020) – Rice University biochemists Michael Stern and James McNew have studied how neurodegeneration kills cells. They’ve conducted countless experiments over more than a decade, and they’ve summarized all they’ve learned in a simple diagram they hope […].
Pharma Times
NOVEMBER 23, 2020
R&D spending in the sector last year represents an eight-year high
Scienmag
NOVEMBER 23, 2020
Rice scientists’ atomic resolution protein models reveal new details about protein binding Credit: Illustration by Mingchen Chen/Rice University HOUSTON – (Nov. 23, 2020) – Knowing precisely where proteins are frustrated could go a long way toward making better drugs. That’s one result of a new study by Rice University scientists looking for the mechanisms that […].
Pharma Times
NOVEMBER 23, 2020
Effectiveness ranges from 62% to 90% depending on dosing regimen
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
340 
Let's personalize your content